Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Monte Rosa Therapeutics ( (GLUE) ) just unveiled an announcement.
Monte Rosa Therapeutics has shared promising interim results from its Phase 1/2 study of MRT-2359, a molecular glue degrader targeting MYC-driven solid tumors. The study highlights a favorable safety profile and optimal degradation of GSPT1 at a recommended 0.5 mg daily dosage on a 21 days on, 7 days off schedule. With ongoing safety assessments in combination therapies and strong trial enrollment, the company plans to release further data in Q1 2025, potentially expanding treatment avenues for patients.
Find detailed analytics on GLUE stock on TipRanks’ Stock Analysis page.
Trending Articles
- Oppenheimer Pounds the Table on Coinbase Stock
- New “Anti-Woke” ETF Targets Starbucks (NASDAQ:SBUX)
- Ford (NYSE:F) Plans New EV Plant
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
